Sinopharm CNBG COVID-19 vaccine
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Sinopharm CNBG COVID-19 vaccine is a COVID-19 vaccine developed by China National Biotec Group (CNBG), a subsidiary of Sinopharm.[1][2]
They claim to be the world's first "second generation" protein recombination vaccine.[3]
References[edit]
- ^ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
- ^ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
- ^ 國藥集團：二代重組蛋白新冠疫苗保護效果良好
 |
Scholia has a profile for Sinopharm CNBG COVID-19 vaccine (Q110291641). |
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |